Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022

  • After a pre-NDA meeting with FDA, Axsome Therapeutics Inc AXSM has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia.
  • The submission is currently anticipated in the fourth quarter of 2022, pending completion of manufacturing and other activities related to the product candidate.
  • AXS-14 has completed two positive placebo-controlled trials, a Phase 3 and a Phase 2 trial, which will be included in the submission.
  • Fibromyalgia is a chronic debilitating disorder characterized by widespread pain, fatigue, disturbed sleep, depression, and cognitive impairment.
  • Approximately 5 million Americans are estimated to suffer from fibromyalgia, with treatment options limited with only three pharmacologic treatments currently approved by the FDA.
  • Price Action: AXSM shares are up 2.6% at $69.28 during the market session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsfibromyalgia
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!